Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Daniel E. Lowther, E. Andres Houseman, Gang Han, Eleni Kleanthous, Dawson Knoblock, Xiangdong Zhou, Shreyan Banerjee, Sagar Patel, David Figueroa

Blood (2022) 140 (Supplement 1): 611–613.

https://doi.org/10.1182/blood-2022-157767

Published: 2022

Journal Articles

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

Ulrich Jaeger, MD, Michael R. Bishop, MD, Gilles Salles, MDPhD, Stephen J. Schuster, MD, Richard T. Maziarz, MD, Xia Han, MS, Alexander Savchenko, MD, Nathan Roscoe, Mbt, Elena Orlando, PhD, Dawson Knoblock, PhD, Ranjan Tiwari, MSc, Lida Bubuteishvili Pacaud, MD, Paolo Corradini

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137045

Published: 2020